Home/Pipeline/RG6356 (DNL310)

RG6356 (DNL310)

Hunter Syndrome (MPS II)

Phase II/IIIActive

Key Facts

Indication

Hunter Syndrome (MPS II)

Phase

Phase II/III

Status

Active

Company

Roche

About Roche

Roche is a global healthcare leader with a unique dual-pillar strategy combining its Pharmaceuticals and Diagnostics divisions to address the full patient journey. Under CEO Thomas Schinecker, the company focuses on preventing disease through early identification, halting progression via targeted therapies, and restoring health with curative medicines. With a market cap of ~$256B, it leverages its integrated platform to drive innovation in oncology, neurology, immunology, and infectious diseases, while pursuing sustainable, long-term growth.

View full company profile

Therapeutic Areas

Oncology Neurology Immunology Infectious Diseases Ophthalmology Rare Diseases

Other Hunter Syndrome (MPS II) Drugs

Drug	Company	Phase	Status
MPS II (Hunter Syndrome) Program	NeuroGT	Pre-clinical	Active
HMI-203	Homology Medicines	Preclinical	Discontinued
JR-141 (pabinafusp alfa)	JCR Pharmaceuticals	Approved	Marketed in Japan/Brazil; Regulatory review elsewhere
DNL310	Denali Therapeutics	Phase 2/3	Active